神经性疼痛是一种常见的间歇性慢性疼痛,影响了全球约7-10%的人口。然而,目前的临床给药方法,如注射和口服给药,主要是一次性管理,不能实现疼痛程度和药物剂量的精确控制。在这里,我们开发了近红外(NIR)光响应微针贴片(MNPs),以根据发作状态时空控制释放的药物剂量,以治疗神经性疼痛。作用机制利用上转换纳米颗粒将NIR光转换为可见光和紫外光。这种转换触发了中孔材料中偶氮苯分子马达的快速旋转,能够按需控制药物剂量的释放。此外,MNs用于以微创和无痛的方式克服角质层的屏障,有效促进药物分子的透皮渗透。这些贴剂的有效性已经通过显著的结果得到证明。在连续五个周期暴露于NIR光后,每个周期持续30秒,贴剂实现了318μg药物的精确释放。在老鼠模型中,在一个周期的NIR光照射1小时内观察到最大的疼痛缓解,效果持续6小时。对于随后的疼痛发作,在相似的光照下保持相同的精确治疗效果。NIR控制的药物精确释放的MNPs为间歇性神经性疼痛的治疗提供了新的范例。
Neuropathic pain is a prevalent form of intermittent chronic pain, affecting approximately 7-10% of the global population. However, the current clinical administration methods, such as injection and oral administration, are mostly one-time administration, which cannot achieve accurate control of pain degree and drug dose. Herein, we developed near-infrared (NIR) light-responsive microneedle patches (MNPs) to spatiotemporally control the drug dose released to treat neuropathic pain according to the onset state. The mechanism of action utilizes upconversion nanoparticles to convert NIR light into visible and ultraviolet light. This conversion triggers the rapid rotation of the azobenzene molecular motor in the mesoporous material, enabling the on-demand controlled release of a drug dose. Additionally, MNs are used to overcome the barrier of the stratum corneum in a minimally invasive and painless manner, effectively promoting the transdermal penetration of drug molecules. The effectiveness of these patches has been demonstrated through significant results. Upon exposure to NIR light for five consecutive cycles, with each cycle lasting 30 s, the patches achieved a precise release of 318 μg of medication. In a mouse model, maximum pain relief was observed within 1 h of one cycle of NIR light exposure, with the effects lasting up to 6 h. The same level of precise treatment efficacy was maintained for subsequent pain episodes with similar light exposure. The NIR-controlled drugs precision-released MNPs provide a novel paradigm for the treatment of intermittent neuropathic pain.